Skip to main content
NewslettersWatchlist

Spruce Biosciences Inc(SPRB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.7388
Day High0.7689
Open:0.7527
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
S&P Futures Climb Ahead of Key U.S. PPI and Retail Sales Data, Adobe Earnings on Tap
Barchart
S&P Futures Tick Higher as Investors Weigh Interest Rate Outlook
Business Wire
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting
Business Wire
Spruce Biosciences to Participate in May Investor Conferences
Business Wire
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
Business Wire
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
Business Wire
Spruce Biosciences Announces $53.6 Million Private Placement Financing
Business Wire
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference
Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Spotlight Growth
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan
Barchart
Pre-Market Brief: Stocks Move Higher Ahead Of Key U.S. Payrolls Data
Business Wire
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
Business Wire
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
Business Wire
Spruce Biosciences to Participate in November Investor Conferences
Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Business Wire
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Business Wire
Spruce Biosciences to Participate in June Investor Conferences
Business Wire
Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
Business Wire
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
Business Wire
Spruce Biosciences to Participate in May Investor Conferences
Business Wire
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
Business Wire
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
Business Wire
Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer
Business Wire
Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022
Business Wire
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
Business Wire
Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
Business Wire
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
Business Wire
Spruce Biosciences Appoints Mike Grey as Interim CEO
Business Wire
Spruce Biosciences to Participate in September Investor Conferences
Business Wire
Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day
Business Wire
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

Profile

Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.